SEC Form 4 · accession 0001209191-15-071125
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory M Weinhoff
Officer — Principal Financial Officer
Period of report
Sep 15, 2015
Accepted (ET)
Sep 17, 2015 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $16.49 | Sep 15, 2015 | A | 454,096 | A | — | Sep 15, 2025 | Common Stock | 454,096 | 454,096 | D |
Explanation of responses
- F1This option vests over a period of four years, with one quarter of the common shares underlying the option vesting August 10, 2016 and the remainder vesting in twelve equal installments on a quarterly basis thereafter. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in issuer's 2015 Equity Incentive Plan.